Navigation Links
Two-Drug Combo Fights Brain Tumors
Date:10/19/2007

Avastin, irinotecan may hit the cancer at different points, researchers say

FRIDAY, Oct. 19 (HealthDay News) -- A combination of the drug bevacizumab (brand name Avastin) and the standard chemotherapy agent irinotecan may benefit patients with a type of deadly brain tumor called glioblastoma multiforme (GBM), says a Duke University pilot study.

This treatment approach may extend the length of time GBM patients can survive without tumor growth and may improve overall survival, according to researchers at Duke's Preston Robert Tisch Brain Tumor Center.

The study included 35 patients whose GBMs returned after they'd had standard therapy, possibly including surgery, radiation and chemotherapy. After the patients received the combination bevacizumab/irinotecan therapy, almost half had no tumor progression after six months, and 80 percent were still alive six months after diagnosis.

The findings are published in the Oct. 20 issue of the Journal of Clinical Oncology.

"These results represent tremendous hope for these patient and their families," lead investigator Dr. James J. Vredenburgh, a neuro-oncologist, said in a prepared statement.

He noted that 75 percent of patients with recurrent GBM treated with standard therapy, such as chemotherapy alone, have tumor progression at six months, and fewer than 50 percent are alive after six months.

"We speculate that bevacizumab and irinotecan each attack a particular characteristic of the tumor independently, or they work together, with bevacizumab suppressing the growth of blood vessels which makes the tumor more susceptible to the chemotherapy," Vredenburgh said.

"Further studies will tease out the exact mechanism of the therapy's success, and we also hope to study the effectiveness of this treatment in patients with newly diagnosed GBM," he added.

More information

The U.S. National Cancer Institute has more about brain tumors.



-- Robert Preidt



SOURCE: Duke University, news release, Oct. 18, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. New Two-Drug Regime To Tackle Malaria
2. Drug Combo Works Better for children with ADHD, Tics
3. Scanning Combo Helps Detect Lung Cancer
4. Relief From Asthma With New Combo Therapy
5. Calcium-Vitamin D Combo For Reduced Fracture Risk
6. Drug Combo Improves Performance Of Multiple Sclerosis Drug
7. Alcohol-illusion: Alcohol and Energy Drinks Combo, Maintains Sobriety?
8. HER-2 Positive Breast Cancer Patients May Benefit With a Combo Drug Strategy
9. The Combo Treatment Is Effective to Treat Type 1 Diabetes in Mice
10. Doomed Duo: Obesity and Type 2 Diabetes Combo, Can Nip Life in the Bud
11. Arimidex-Herceptin Combo Therapy For Breast Cancer-Clinical Trial Findings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/26/2016)... ... , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... a whole new perspective by using the title layers in ProSlice Levels to ... ProSlice Levels contains over 30 Different presets to choose from. FCPX users ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets has ... Market Analysis 2016 - Forecast to 2022" report to ... report contains up to date financial data derived from varied ... major trends with potential impact on the market during the ... segmentation which comprises of sub markets, regional and country level ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
(Date:6/23/2016)... June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations ... Latin America . ... ... ... ...
Breaking Medicine Technology: